Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70038 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Sagar S Bachhav und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Inc, North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Antibodies, Monoclonal. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Demenz
Abstract (Originalsprache)
To inform an efficient development of new investigational anti‐amyloid beta (anti‐Aβ) monoclonal antibodies (mAbs), a modeling‐and‐simulation‐based strategy was proposed. A general modeling framework that links drug exposures to the time course of amyloid plaque removal and amyloid‐related imaging abnormalities characterized by edema and effusion (ARIA‐E) was developed based on publicly available data on aducanumab, lecanemab, and donanemab. A non‐linear mixed effect model with shared model parameters described the dose response data from aducanumab, lecanemab, and donanemab studies after adjusting for different potency for different antibodies, which allowed the rate of amyloid plaque removal to vary by drug. A time‐to‐event model was developed to describe ARIA‐E incidence. The model assumes that ARIA‐E incidence rate is dependent on the rate of amyloid plaque removal with a drug‐dependent scaling factor linking amyloid plaque removal rate and treatment‐dependent hazard. Simulations of amyloid plaque removal and ARIA‐E for a hypothetical anti‐Aβ mAb based on certain assumptions and scenarios provided insights into possible outcomes. Overall, the meta‐analysis of published data on existing anti‐Aβ mAbs could be utilized to model exposure‐response relationships and the time course of amyloid plaque removal and ARIA‐E incidence of new anti‐Aβ mAbs and to inform the design of early clinical trials for them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, AbbVie Inc, North Chicago, Illinois, USA.
- Clinical Pharmacology, AbbVie Deutschland GmbH Co. KG, Ludwigshafen am Rhein, Germany.
ORCID-Profile: Sagar S Bachhav, Ana Victoria Ponce-Bobadilla, Diana Clausznitzer, Sven Stodtmann, Hao Xiong
Zitieren
APA
Bachhav, S. S., Ponce-Bobadilla, A. V., Clausznitzer, D., Stodtmann, S., & Xiong, H. (2025). Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70038
Vancouver
Bachhav SS, Ponce-Bobadilla AV, Clausznitzer D, Stodtmann S, Xiong H. Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70038
BibTeX
@article{Bachhav2025,
author = {Bachhav, Sagar S and Ponce-Bobadilla, Ana Victoria and Clausznitzer, Diana and Stodtmann, Sven and Xiong, Hao},
title = {Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70038}
}
EUVIMED